In vitro study of cyclosporine A 0.05 % on primary and recurrent pterygium fibroblasts

详细信息    查看全文

• 作者：Magda Massae Hata Viveiros ; Fabiano Yutaka Kakizaki…
• 关键词：Cyclosporine ; Pterygium ; Fibroblasts ; In vitro
• 刊名：International Ophthalmology
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：36
• 期：2
• 页码：237-242
• 全文大小：390 KB
• 参考文献：1.Serracarbassa LL, Dantas MCN (1999) Disordens degenerativas da conjuntiva-córnea-esclera. In: Lima, Dantas MCN; Alves, MR. Doenças externas oculares e córnea—Manual do CBO. Cult Méd São Paulo 8:371–374
  2.Alves MRA (1999) Pterígio In: Conjuntiva Cirúrgica. Roca São Paulo 8:59–66
  3.Cameron ME (1983) Histology of pterygium: an electron microscopic study. Br J Ophthalmol 67:604–608CrossRef PubMed PubMedCentral
  4.Cardillo JA, Alves MR, Kara José N, Trajan Neto A, Serpa JF, Ambrósio LE (1995) Uso tópico pós-operatório versus aplicação intra-operatória da mitomicina C a 0,02% na prevenção de recidivas. Arq Bras Oftalmol 58(6):413–415
  5.Cardillo JA, Kara José N, Alves MR, Poterio MB, Coelho RP, Ambrósio LE (1995) Instilação do colírio de mitomicina C no pós-operatório do pterígio primário. Arq Bras Oftalmol 58(2):138–140
  6.Cardillo JA, Alves MR, Kara José N, Camargo JCF, Serpa JF, Ambrósio LE et al (1996) Eficácia da mitomicina C a 0,04% na prevenção de recidivas do pterígio primário: aplicação intra-operatória versus uso tópico pós-operatório. Rev Bras Oftalmol 55(6):15–18
  7.Rubinfeld RS, Stein RM (1997) Topical mitomycin C for pterygia: is single application appropriate? Ophthal Surg Lasers 28(8):662–669
  8.Kheirkhah A, Hashemi H, Adelpour M, Nikdel M, Rajabi MB, Behrouz MJ (2012) Randomized trial of pterygium surgery with mitomycin C application using conjunctival autograft versus conjunctival-limbal autograft. Ophthalmology 119(2):227–232CrossRef PubMed
  9.Young AL, Ho M, Jhanji V, Cheng LL (2013) Ten-year results of a randomized controlled trial comparing 0.02 % mitomycin C and limbal conjunctival autograft in pterygium surgery. Ophthalmology 120(12):2390–2395CrossRef PubMed
  10.Malek I, Zghal I, Chebbi A, Lajili Z, Boujemaa C, Nacef L, Bouguila H, Saida Ayed S (2013) Conjunctival limbal autograft versus simple excision with intra-operative mitomycin C in pterygium surgery: a comparative study. J Fr Ophtalmol 36(3):230–235CrossRef PubMed
  11.Schellini AS, Shiratori CN, Spirandelli PH, Shiratori CA, Padovani CR (2000) Uso do 5-fluorouracil no intra-operatório da cirurgia do pterígio. Arq Bras Oftalmol 63(2):111–114CrossRef
  12.Shiratori CA, Hoyama E, Schellini SA, Padovani CR (2003) Infiltração de 5-fluorouracil no pré-operatório do pterígio. Arq Bras Oftalmol 66(4):499–503CrossRef
  13.Valezi VG, Schellini SA, Viveiros MMH, Padovani CR (2009) Segurança e efetividade no tratamento do Pterígio usando infiltração de 5-fluoruracil no intraoperatório. Arq Bras Oftalmol 72:169–173CrossRef PubMed
  14.Viveiros MMH, Schellini SA, Candeias J, Padovani CR (2007) Exposure of normal Tenon’s capsule fibroblasts from pterygium to 5-fluorouracil and mitomycin C. Arq Bras Oftalmol 70(1):73–77CrossRef PubMed
  15.Bekibele CO, Ashaye A, Olusanya B, Baiyeroju A, Fasina O, Ibrahim AO, Ogun O (2012) 5-Fluorouracil versus mitomycin C as adjuncts to conjunctival autograft in preventing pterygium recurrence. Int Ophthalmol 32(1):3–8CrossRef PubMed
  16.Shahin MM, Elbendary AM, Elwan MM (2012) Intraoperative subconjunctival bevacizumab as an adjunctive treatment in primary pterygium: a preliminary report. Ophthalmic Surg Lasers Imaging 43(6):459–466CrossRef PubMed
  17.Hu Q, Qiao Y, Nie X, Cheng X, Ma Y (2014) Bevacizumab in the treatment of pterygium: a meta-analysis. Cornea 33(2):154–160CrossRef PubMed
  18.Lekhanont K, Patarakittam T, Thongphiew P, Suwan-apichon O, Hanutsaha P (2012) Randomized controlled trial of subconjunctival bevacizumab injection in impending recurrent pterygium: a pilot study. Cornea 31(2):155–161CrossRef PubMed
  19.Gu L, Jin W, Kan L, Wang X et al (2015) A retrospective study to compare the use of tacrolimus and cyclosporine in combination with adriamycin in post-transplant liver cancer patients. Cell Biochem Biophys 71(2):565–570. doi:10.​1007/​s12013-014-0235-7
  20.Umeda K, Adachi S, Tanaka S, Ogawa A, et al (2014) Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation. Pediatr Blood Cancer. doi:10.​1002/​pbc.​25243
  21.Willis L, RExwinkle A, Bryan J, Kadia TM (2014) Recent developments in drug therapy for aplastic anemia. Ann Pharmacother 48(11):1469–1478. doi:10.​1177/​1060028014547078​
  22.Borel JF (2002) History of the discovery of ciclosporin and of its early    pharmacological developement. Wien Klin Wochenschr 114(12):433–437
  23.Tedesco D, Haragsim L (2012) Cyclosporine: a review. J Transplant. Article ID 230386. doi:10.​1155/​2012/​230386
  24.Perry HD, Donnenfeld ED (2004) Topical 0,05% cyclosporin in the treatment of dry eye. Expert Opin Pharmacother 5(10):2099–2107CrossRef PubMed
  25.Schultz C (2014) Safety and efficacy of cyclosporine in the treatment of chronic dry eye. Ophthalmol Eye Dis 24(6):37–42CrossRef
  26.Zhou XQ, Wei RL (2014) Topical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysis. Cornea 33(7):760–767CrossRef PubMed
  27.Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R et al (2002) Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 89(3):289–303CrossRef
  28.Keklikci U, Dursun B, Cingu AK (2014) Topical cyclosporine A 0.05% eyedrops in the treatment of vernal keratoconjunctivitis—randomized placebo-controlled trial. Adv Clin Exp Med 23(3):455–461CrossRef PubMed
  29.Erdinest N, Solomon A (2014) Topical immunomodulators in the management of allergic eye diseases. Curr Opin Allergy Clin Immunol 14(5):457–463CrossRef PubMed
  30.Leonardi A (2013) Management of vernal Keratoconjunctivitis. Ophthalmol Ther 2(2):73–88CrossRef PubMed PubMedCentral
  31.Wan XC, Dimov V (2014) Pharmacokinetic evaluation of topical calcineurin inhibitors for treatment of allergic conjunctivitis. Expert Opin Drug Metab Toxicol 10(4):543–549CrossRef PubMed
  32.Pflugfelder SC, Karpecki PM, Perez VL (2014) Treatment of blepharitis: recent clinical trials. Ocul Surf 12(4):273–284CrossRef PubMed
  33.Hasanreisoglu M, Avisar R (2008) Long-term topical cyclosporin A therapy in Thygeson’s superficial punctate keratitis: a case report. Cases J 23(1):415CrossRef
  34.Ragam A, Kolomeyer AM, Kim JS, Nayak NV et al (2014) Topical cyclosporine 1 % for the treatment of chronic ocular surface inflammation. Eye Contact Lens 40(5):283–288CrossRef PubMed
  35.Arevalo JF, Lasave AF, Jindan MY, Al Sabaani NA et al (2015) Uveitis in Behçet Disease in a Tertiary Center Over 25 Years: The KKESH Uveitis Survey Study Group. Am J Ophthalmol 159(1):177–184CrossRef PubMed
  36.Wu H, Chen G (1999) Cyclosporine A and thiotepa in prevention of postoperative recurrence of pterygium. Yan Ke Xue Bao 15(2):91–92PubMed
  37.Hasegawa DS, Hoyama E, Dalamas JC, Hasegawa N, Yagui N (2006) Uso de ciclosporina 0.05% colírio no pós-operatório do pterígio (abstract). In: XXX international congress of ophthalmology, São Paulo, 19–24 February 2006. Abstract book. p 64
  38.Turan-Vural E, Torun-Acar B, Kivanc SA, Acar S (2011) The effect of topical 0.05% cyclosporine on recurrence following pterygium surgery. Clin Ophthalmol 5:881–885CrossRef PubMed PubMedCentral
  39.Özülken K, Koç M, Ayar O, Hasiripi H (2012) Topical cyclosporine A administration after pterygium surgery. Eur J Ophthalmol 22(7):5–10CrossRef
  40.Aydin A, Karadayi K, Aykan U, Can G, Colakoglu K, Bilge AH (2008) Effectiveness of topical ciclosporin A treatment after excision of primary pterygium and limbal conjunctival autograft. J Fr Ophtalmol 31(7):699–704CrossRef PubMed
  41.Yalcin Tok O, Burcu Nurozler A, Ergun G, Akbas Kocaoglu F, Duman S (2008) Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica 222(6):391–396CrossRef PubMed
  42.Hercules LA, Viveiros MMH, Schellini AS, Candeias J, Padovani CR (2006) Exposure of Tenon’s capsule fibroblasts of pterygium to cyclosporin 0.05%. Arq Bras Oftalmol 69(6):831–835CrossRef PubMed
  43.Viveiros MMH, Schellini AS, Rainho C, Rogatto SR, Padovani CR (2004) Análise do cultivo de fibroblastos da cáspula de Tenon de pterígios primários e recidivados. Arq Bras Oftalmol 67(supl 4):37
  44.Hill JC, Maske R (1989) Pathogenesis of pterygium. Eye 3(2):218–226CrossRef PubMed
  45.Di Girolano N, Kumar RK, Coroneo MT, Wakefield D (2002) UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Inv Ophthalmol Vis Sci 43(11):3430–3437
  46.Nussenblatt RB, Palestine AG (1986) Cyclosporine: immunology, pharmacology and therapeutic uses. Surv Ophthalmol 31:159–169CrossRef PubMed
  47.Strober W (2001) Trypan blue exclusion test of cell viability. Curr Protoc Immunol. Appendix 3: Appendix 3B. doi:10.​1002/​0471142735
  48.Piccinini F, Tesei A, Paganelli G, Zoli W, Bevilacqua A (2014) Improving reliability of live/dead cell counting through automated image mosaicing. Comput Methods Programs Biomed 117(3):448–463. doi:10.​1016/​j CrossRef PubMed
  
• 作者单位：Magda Massae Hata Viveiros (1) (2)
  Fabiano Yutaka Kakizaki (2)
  Laura Almeida Hércules (2)
  Carlos Roberto Padovani (3)
  João Manuel Grisi Candeias (4)
  Silvana Artioli Schellini (2)
  
  1. Post-Doctoral of the General Basis of Surgery Post Graduation Program of Botucatu Medical School, Universidade Estadual Paulista – UNESP de Botucatu, São Paulo, Brazil
  2. Department of Ophthalmology, Botucatu Medical School, Universidade Estadual Paulista – UNESP de Botucatu, São Paulo, Brazil
  3. Department of Biostatistic, Biosciences Institute, Universidade Estadual Paulista – UNESP de Botucatu, São Paulo, Brazil
  4. Department of Microbiology and Immunology, Biosciences Institute, Universidade Estadual Paulista - UNESP de Botucatu, São Paulo, Brazil
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Ophthalmology
  
• 出版者：Springer Netherlands
• ISSN：1573-2630

文摘

To compare the cyclosporine 0.05 % exposure effect on fibroblasts from primary and recurrent pterygium. Primary culture of fibroblasts from primary and recurrent pterygium was performed until the third passage, which was exposed to cyclosporine 0.05 % in a group and the other remaining unexposed (control group), in triplicates. After 3, 6, 12, and 17 days of exposure the viable cell counting was performed by hemocytometer. The results were statistically analyzed using the technique of analysis of non-parametric variance model for repeated measures with three factors. There was a significant reduction in both fibroblast proliferation, in primary as in the recurrent pterygium cultures exposed to cyclosporine when compared not exposed cultures, with statistical significance (P < 0.05). Comparing primary and recurrent pterygium that received the drug, there was no significant difference in cell proliferation in relation to primary or recurrent pterygium. Cyclosporine 0.05 % is effective in inhibiting fibroblast proliferation in culture, both in primary and as in recurrent pterygium.